The Transboro project was presented in Novara, with a focus on BNCT, which uses boron and neutrons to treat tumors. Prof. Panza explained how this therapy is targeted and specific, able of destroying cancer cells sparing healthy ones. He discussed the historical difficulties in producing neutrons, which until 2010 were available only through nuclear reactors, and pointed out how new accelerators have rekindled interest in this therapy. In addition, he emphasized the importance of developing new compounds or carriers to improve treatment efficacy.
Prof. Miggiano described the activities of his laboratory, focusing on the engineering of vectors for boron transport in cancer cells and the importance of recombinant DNA technology and protein purification and characterization.
Prof. Bortolussi then explained the operation of the Pavia nuclear reactor, highlighting its power and ability to generate neutrons with specific energy characteristics. During the discussion, clinical cases were shared, highlighting the surgical challenges and complexity of autotransplantation. She also described autoradiography techniques for quantification and distribution of boron at the cellular level.
Dr. Jermini introduced the company EXERIS BIO, recounting the history of the company, its organization, and its involvement in the project, then bringing the industrial point of view and emphasizing the synergy between the research and development carried out by the university partners and the application potential of the company partners' expertise.
Dr. Brook introduced BRICK42 and its corporate specificities, with a special focus on aspects of dissemination of results, which will play a key role in the development of the project.
Dr. Recchia, representing Regione Lombardia, explained the management and administrative aspects required of the partners, which, together with the more strictly scientific and applicative aspects, are an essential part of the proper conduct of the project.